HBI-3000
Phase 2Small molecule
HBI-3000 is one of 23 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Xylocaine
MMEDRx USA, Inc.
Preclinical
Anticoagulants
SanofiPreclinical
Direct Anticoagulant
BayerPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Statin
Bristol-Myers SquibbPreclinical
HBI-3000
HHUYABIO International, LLC.
Phase 2
Warfarin Sodium
Boehringer IngelheimPreclinical
Magnesium SO4
HHospital de Base
Preclinical
Medication
NNYU Langone Health
Preclinical
Anticoagulation
HHospital Álvaro Cunqueiro
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HBI-3000. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHUYABIO International, LLC.